US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

1.86

+0.10005.68%

Post-market: 1.860.0046+0.25%19:59 EDT

Volume:542.03K

Turnover:981.09K

Market Cap:200.88M

PE:-3.41

High:1.86

Open:1.78

Low:1.73

Close:1.76

52wk High:6.30

52wk Low:1.58

Shares:108.00M

Float Shares:94.28M

Volume Ratio:1.24

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5461

EPS(LYR):-0.4448

ROE:-757.48%

ROA:-37.70%

PB:16.02

PE(LYR):-4.18

Loading ...

Overview Company News Filings

Nervgen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Q2 2026 Loss Reflects Continued Spending on NVG-291, NVG-300 Development, Company Says

Press Release: NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright

Nervgen Pharma Initiated at Outperform by Leerink Partners

Nervgen Pharma Corp : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $10

THOMSON REUTERS

Nervgen Pharma Launches US$ 50 Million At-the-market Equity Offering Via Leerink Partners

H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)

H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)

NervGen Pharma initiated with a Buy at TD Cowen

NervGen prices 24,000,000-share offering with warrants at US$2.5, targets US$60 million gross proceeds

Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors

NervGen Pharma files $250M mixed securities shelf

NervGen Pharma Increases Mixed Shelf Offering to $250 Mln From $150 Mln - SEC Filing

THOMSON REUTERS

NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291

NervGen says NVG-291 improves gait quality in Phase 1b/2a chronic tetraplegia study

NervGen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement in Phase 1B/2a Connect Sci Study

THOMSON REUTERS

NervGen Pharma Corp - on Track to Initiate Phase 3 Restore Study in Mid-2026

THOMSON REUTERS

NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus

BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/NGEN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGEN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":1.86,"timestamp":1787342400000,"preClose":1.76,"halted":0,"volume":542033,"hourTrading":{"tag":"盘后","latestPrice":1.8646,"preClose":1.86,"latestTime":"19:59 EDT","volume":1071,"amount":1986.7876,"timestamp":1787356776851,"change":0.0046,"changeRate":0.002473,"amplitude":0.018602},"delay":0,"changeRate":0.05681818181818187,"floatShares":94281199,"shares":108000000,"eps":-0.546059,"marketStatus":"Market Closed","change":0.1,"latestTime":"08-21 16:00:00 EDT","open":1.78,"high":1.86,"low":1.7269,"amount":981087.5352752,"amplitude":0.075625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.546059,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.76,"preHourTrading":{"tag":"盘前","latestPrice":1.75,"preClose":1.76,"latestTime":"09:00 EDT","volume":236,"amount":414.3536016,"timestamp":1787317237196,"change":-0.01,"changeRate":-0.005682,"amplitude":0.016023},"postHourTrading":{"tag":"盘后","latestPrice":1.8646,"preClose":1.86,"latestTime":"19:59 EDT","volume":1071,"amount":1986.7876,"timestamp":1787356776851,"change":0.0046,"changeRate":0.002473,"amplitude":0.018602},"volumeRatio":1.2377262482049183,"impliedVol":0.0812,"impliedVolPercentile":0.1497},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","floatShares":94281199,"roa":"-37.70%","roe":"-757.48%","lyrEps":-0.444846,"volumeRatio":1.2377262482049183,"shares":108000000,"dividePrice":0,"high":1.86,"amplitude":0.075625,"preClose":1.76,"low":1.7269,"week52Low":1.58,"pbRate":"16.02","week52High":6.3,"institutionHeld":0,"latestPrice":1.86,"eps":-0.546059,"divideRate":0,"volume":542033,"delay":0,"ttmEps":-0.546059,"open":1.78,"prevYearClose":5.6,"prevWeekClose":1.735,"prevMonthClose":1.62,"prevQuarterClose":2.06,"fiveDayClose":1.735,"twentyDayClose":1.63,"sixtyDayClose":2.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGEN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"NGEN","fiscalQuarterEnding":"2026/06","expectedEps":-0.09,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2026-05-15","symbol":"NGEN","fiscalQuarterEnding":"2026/03","expectedEps":-0.07,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.09},{"date":"2026-03-31","symbol":"NGEN","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"Pre-MKt","dateTimestamp":1774929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGEN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGEN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGEN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGEN","date":"2026-08-21","current":-3.406225,"percent":0.973856,"low":-25.148356,"twenty":-17.441707,"median":-9.728074,"eighty":-6.591693,"high":-4.008234,"avg":-11.783719,"sd":5.689592,"marketCap":189239834},"quantilePoints":[{"date":"2026-01-09","current":-25.148356,"twenty":-24.98651,"median":-24.743741,"eighty":-24.500973,"marketCap":463798962.95},{"date":"2026-01-16","current":-23.484013,"twenty":-24.651705,"median":-24.262661,"eighty":-23.546305,"marketCap":432253265.53},{"date":"2026-01-23","current":-22.238177,"twenty":-24.339127,"median":-23.484013,"eighty":-22.456198,"marketCap":412101315.23},{"date":"2026-01-30","current":-17.441707,"twenty":-24.262661,"median":-22.611928,"eighty":-20.307131,"marketCap":329508465.32},{"date":"2026-02-06","current":-16.382746,"twenty":-23.795472,"median":-22.238177,"eighty":-17.908896,"marketCap":306238051.42},{"date":"2026-02-13","current":-17.441707,"twenty":-23.484013,"median":-19.886661,"eighty":-17.285978,"marketCap":327197651.85},{"date":"2026-02-20","current":-18.220355,"twenty":-23.359429,"median":-18.282647,"eighty":-17.285978,"marketCap":340388899.6},{"date":"2026-02-27","current":-17.753166,"twenty":-22.879782,"median":-18.03348,"eighty":-17.410561,"marketCap":331850071.27},{"date":"2026-03-06","current":-17.223686,"twenty":-22.51849,"median":-17.893323,"eighty":-17.27352,"marketCap":321208516.98},{"date":"2026-03-13","current":-16.382746,"twenty":-22.306698,"median":-17.753166,"eighty":-16.993207,"marketCap":307553178.63},{"date":"2026-03-20","current":-16.957011,"twenty":-22.250635,"median":-17.753166,"eighty":-16.888553,"marketCap":316207550},{"date":"2026-03-27","current":-15.785094,"twenty":-21.714925,"median":-17.597437,"eighty":-16.837477,"marketCap":291516280},{"date":"2026-04-02","current":-18.89617,"twenty":-20.942507,"median":-17.535145,"eighty":-16.702393,"marketCap":347270760},{"date":"2026-04-10","current":-10.676925,"twenty":-19.970755,"median":-17.441707,"eighty":-16.494872,"marketCap":340718966},{"date":"2026-04-17","current":-10.464421,"twenty":-19.238183,"median":-17.254832,"eighty":-16.110604,"marketCap":336672423},{"date":"2026-04-24","current":-9.863583,"twenty":-18.837636,"median":-17.005665,"eighty":-12.953446,"marketCap":318058323},{"date":"2026-05-01","current":-9.064424,"twenty":-18.587877,"median":-16.950192,"eighty":-10.62677,"marketCap":293779061},{"date":"2026-05-08","current":-9.632569,"twenty":-18.344939,"median":-16.86331,"eighty":-10.287304,"marketCap":311583853},{"date":"2026-05-15","current":-9.34654,"twenty":-18.295105,"median":-16.834362,"eighty":-10.043494,"marketCap":300253531},{"date":"2026-05-22","current":-9.812417,"twenty":-18.145605,"median":-16.66306,"eighty":-9.800918,"marketCap":297825605},{"date":"2026-05-29","current":-7.287863,"twenty":-18.008563,"median":-16.66306,"eighty":-9.72533,"marketCap":220902522},{"date":"2026-06-05","current":-7.091826,"twenty":-17.902667,"median":-16.382746,"eighty":-9.634252,"marketCap":213468303},{"date":"2026-06-12","current":-6.717699,"twenty":-17.87775,"median":-16.216296,"eighty":-9.423447,"marketCap":200723927},{"date":"2026-06-18","current":-7.855923,"twenty":-17.87775,"median":-15.872071,"eighty":-9.364073,"marketCap":232584867},{"date":"2026-06-26","current":-6.880017,"twenty":-17.753166,"median":-13.39003,"eighty":-9.064424,"marketCap":202847989},{"date":"2026-07-02","current":-7.524736,"twenty":-17.753166,"median":-10.756935,"eighty":-7.674051,"marketCap":221964554},{"date":"2026-07-10","current":-6.687968,"twenty":-17.753166,"median":-10.600843,"eighty":-7.470839,"marketCap":197537832},{"date":"2026-07-17","current":-5.950494,"twenty":-17.703333,"median":-10.394273,"eighty":-7.2635,"marketCap":177359237},{"date":"2026-07-24","current":-5.990968,"twenty":-17.616125,"median":-10.19196,"eighty":-7.15871,"marketCap":177890252},{"date":"2026-07-31","current":-5.701372,"twenty":-17.597437,"median":-10.084942,"eighty":-7.057391,"marketCap":170260212},{"date":"2026-08-07","current":-6.137986,"twenty":-17.522687,"median":-9.917992,"eighty":-6.810664,"marketCap":183029728},{"date":"2026-08-14","current":-6.239509,"twenty":-17.454165,"median":-9.793252,"eighty":-6.730479,"marketCap":187286234},{"date":"2026-08-21","current":-4.207016,"twenty":-17.441707,"median":-9.728074,"eighty":-6.591693,"marketCap":189239834}],"updateTime":1787472386689},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGEN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659015237","title":"Nervgen Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659015237","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659015237?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:35","pubTimestamp":1786624528,"startTime":"0","endTime":"0","summary":"BRIEF-Nervgen Reports Second Quarter 2026 Financial Results And Provides Business UpdatesAug 13 (Reuters)-NervGen Pharma CorpNGEN.O:NERVGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESSource text:ID:nGNX9SXjX0Further company coverage:NGEN.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA1DRDGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154354","title":"NervGen Q2 2026 Loss Reflects Continued Spending on NVG-291, NVG-300 Development, Company Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154354?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:08","pubTimestamp":1786622912,"startTime":"0","endTime":"0","summary":"NervGen Q2 2026 loss reflects continued spending on NVG-291, NVG-300 development, company saysNervGen’s commentary for the three and six months ended June 30, 2026 centered on continued spending tied ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL46qz6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159089","title":"Press Release: NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159089?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620600,"startTime":"0","endTime":"0","summary":"-- Site activation and screening for the Phase 3 RESTORE study is expected. to begin in September 2026, with the first participant anticipated to be. -- Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief. Financial Officer and Marissa Volpe as SVP, Clinical Development.-- C$86.8 million  in cash and cash equivalents as of June. 30, 2026, which is expected to fund operations through anticipated. topline data readout from RESTORE in 1H 2028.-- Company plans to host inaugural R&D Day in Fall 2026, bringing together. activation and screening for the Phase 3 RESTORE study is expected to. a Phase 3 registrational study of NVG-291 in individuals with chronic. improvement in gait quality across established hallmarks of SCI-specific. strengthening the Company's balance sheet and extending its expected","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","LU1892829315.USD","BK4192","NGEN","SCI","BK4548","BK4007","LU0077335932.USD","LU1291159041.SGD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171427","title":"NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651171427?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023213,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on NervGen Pharma (NGEN) to $15 from $18 and keeps a Buy rating on the s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-lowered-to-15-from-18-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-lowered-to-15-from-18-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651214618","title":"Nervgen Pharma Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2651214618","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651214618?lang=en_us&edition=fundamental","pubTime":"2026-07-14 02:09","pubTimestamp":1783966140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGEN/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 14:09 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651130118","title":"Nervgen Pharma Corp : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2651130118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651130118?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:07","pubTimestamp":1783937220,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648767635","title":"Nervgen Pharma Launches US$ 50 Million At-the-market Equity Offering Via Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2648767635","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648767635?lang=en_us&edition=fundamental","pubTime":"2026-07-03 05:24","pubTimestamp":1783027481,"startTime":"0","endTime":"0","summary":"NervGen Pharma launches US$ 50 million at-the-market equity offering via Leerink PartnersNervGen Pharma entered an at-the-market sales agreement with Leerink Partners to offer up to USD 50 million of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL3xCpYv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","BK4207","NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646808486","title":"H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646808486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646808486?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:35","pubTimestamp":1782390956,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on NervGen Pharma, with a price target of $18.00. Selvaraju ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280536","title":"H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280536?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:46","pubTimestamp":1781185574,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on NervGen Pharma on June 8 and set a price target of $18.00. Selvaraju covers the He...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642283168","title":"NervGen Pharma initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2642283168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642283168?lang=en_us&edition=fundamental","pubTime":"2026-06-11 17:51","pubTimestamp":1781171468,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of NervGen Pharma (NGEN) with a Buy rating and no price target The company is advancing treatments of neurotraumatic an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NGEN","BK4585","COWN","TD","BK4127","BK4566","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640967937","title":"NervGen prices 24,000,000-share offering with warrants at US$2.5, targets US$60 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2640967937","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640967937?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:30","pubTimestamp":1780349414,"startTime":"0","endTime":"0","summary":"NervGen priced an underwritten follow-on public offering of 24,000,000 common shares with warrants to buy up to 24,000,000 shares.Offering price set at US$ 2.5 per common share and accompanying warrant; gross proceeds about US$ 60 million, excluding warrant exercises.Warrants carry a US$ 3.68 exercise price, are immediately exercisable, and expire five years from issuance.Net proceeds earmarked to advance NVG-291 clinical studies, with remaining funds for general corporate purposes.PFP Biosciences participated; post-offering stake 15,488,673 shares  with 8,144,335 warrants, capped at 19.99% ownership on exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this new","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5jwN4t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639679718","title":"Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2639679718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639679718?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:32","pubTimestamp":1780072349,"startTime":"0","endTime":"0","summary":"Nervgen Pharma Corp ($NGEN) announced an update on their ongoing clinical study. The CONNECT study, officially titled “A Randomized, Double-Blind, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nervgens-connect-trial-termination-what-it-means-for-ngen-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nervgens-connect-trial-termination-what-it-means-for-ngen-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","NGEN","BK4007","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510128","title":"NervGen Pharma files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510128","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638510128?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802110,"startTime":"0","endTime":"0","summary":"09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510867","title":"NervGen Pharma Increases Mixed Shelf Offering to $250 Mln From $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638510867?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638115375","title":"NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291","url":"https://stock-news.laohu8.com/highlight/detail?id=2638115375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638115375?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:39","pubTimestamp":1779795589,"startTime":"0","endTime":"0","summary":"NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-announces-biomechanical-gait-analyses-on-recovery-with-nvg-291-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-announces-biomechanical-gait-analyses-on-recovery-with-nvg-291-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVG","BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519375","title":"NervGen says NVG-291 improves gait quality in Phase 1b/2a chronic tetraplegia study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519375","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519375?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:15","pubTimestamp":1779794124,"startTime":"0","endTime":"0","summary":"NervGen reported new independent, blinded gait-analysis results from its Phase 1b/2a CONNECT SCI trial of NVG-291 in chronic tetraplegia.The analysis indicated patients on NVG-291 showed signs consistent with genuine neural recovery, not compensatory movement, versus placebo.The findings support earlier reported improvements across multiple functional measures, reinforcing the program’s clinical signal in a chronic population.The update underpins plans to start the Phase 3 RESTORE registrational study in mid-2026, with site activation underway.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLrj2p9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","BK4007","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","NGEN","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519311","title":"NervGen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement in Phase 1B/2a Connect Sci Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519311?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:15","pubTimestamp":1779794121,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230FT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638315519","title":"NervGen Pharma Corp - on Track to Initiate Phase 3 Restore Study in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638315519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638315519?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:15","pubTimestamp":1779794121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230FT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638408304","title":"NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2638408304","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638408304?lang=en_us&edition=fundamental","pubTime":"2026-05-25 02:15","pubTimestamp":1779646539,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Justin Keywood reiterated a Buy rating on NervGen Pharma on May 21 and set a price target of $6.00. Keywood covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-receives-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-receives-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4007","BK4127","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637319930","title":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2637319930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637319930?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:41","pubTimestamp":1779450076,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL6N41Z0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1691799644.USD","BK4534","IE00BLSP4239.USD","LU1861559042.SGD","NGEN","LU1280957306.USD","IE0009356076.USD","LU2324357040.USD","LU2112291526.USD","RGTX","LU0070302665.USD","BK4141","BK4613","LU0130517989.USD","LU2517655028.SGD","LU0061475181.USD","SGXZ57979304.SGD","BK4505","LU1430594728.SGD","IE0004445239.USD","LU2023250843.SGD","LU0098860793.USD","LU1037948897.HKD","LU1989773731.SGD","LU2237438978.USD","LU0211331839.USD","FUTU","LU0965509283.SGD","LU1934455863.HKD","BK4566","LU2125909247.SGD","IE00B1BXHZ80.USD","LU2404859667.USD","LU2404859741.USD","BJ","LU1048588211.SGD","BK4023","IE00BJJMRZ35.SGD","LU2210149790.SGD","BK4094","LU2264538146.SGD","LU1291159041.SGD","LU1046421795.USD","BK4602","LU0106261372.USD","LU0208291251.USD","LU1066053197.SGD","LU2265009873.SGD","MRK","LU1201861249.SGD","SG9999013999.USD","SG9999014559.SGD","SG9999015358.SGD","ZM","QBTX","IE000M9KFDE8.USD","LU0130102774.USD","LU1064131342.USD","LU1989772923.USD","LU1035773651.USD","SG9999014542.SGD","LU0348766576.USD","LU0985320562.USD","LU1974910355.USD","LU1941712264.USD","BK4509","LU2125909593.SGD","FUTG","LU0648001328.SGD","LU1988902786.USD","LU2210150020.SGD","LU0859254822.USD","LU2125154778.USD","BK4551","LU0690374961.EUR","BK4155","LU0690374615.EUR","EL","LU2491049909.HKD","BK4554","LU1116320901.HKD","BK4017","IE00B5949003.HKD","BK4548","LU1069347547.HKD","LU2491050071.SGD","LU0320765489.SGD","LU1981816686.USD","LU2506952170.USD","QBTZ","BK4532","LU1935043536.SGD","LU0265550359.USD","LU1323610961.USD","LU2506952097.USD","IE00BJT1NW94.SGD","SG9999014575.USD","LU1093756168.USD","LU2106854487.HKD","LU0203347892.USD","BK4559","LU1861215975.USD","SG9999001176.SGD","LU2461242641.AUD","BK4535","LU0203345920.USD","LU0942090050.USD","RGTU","IE00BLSP4452.SGD","BK4558","LU0072462343.USD","LU1066051498.USD","LU0861579265.USD","LU0950375773.USD","TTWO","LU0719512351.SGD","BK4585","LU0980610538.SGD","LU2552382058.USD","LU0314104364.USD","LU0477156953.USD","LU2517655291.USD","BK4503","LU2433249047.HKD","LU1057294990.SGD","LU2023250504.SGD","LU2361044949.HKD","SG9999014567.USD","PPTA","LU1037948541.HKD","BK4007","LU1116320737.USD","LU0266013472.USD","LU1823568750.SGD","BK4526","LU2506951958.HKD","LU2552382215.SGD","LU1861558580.USD","LU0348767384.USD","SG9999002232.USD","LU1066051225.USD","BK4183","IE00BSNM7G36.USD","LU1585245621.USD","LU2517655374.HKD","DNLI","BK4516","BK4533","LU1571399168.USD","LU0868494617.USD","LU2491050154.USD","BK4085","LU0265550946.USD","LU1861220033.SGD","BK4550","LU0122379950.USD","LU1989772840.SGD","LU0238689110.USD","LU2125154935.USD","RGTZ","IE00BN8TJ469.HKD","SG9999002463.SGD","LU0823417653.USD","LU2552382132.HKD","LU1023059063.AUD","LU2361044865.SGD","LU0058720904.USD","LU0081259029.USD","LU2360107168.USD","LU1699723380.USD","SG9999015341.SGD","BK4524","LU1934455194.USD","QBTS","LU0823417737.USD","BK4139","IE0002141913.USD","IE00B4R5TH58.HKD","LU0234572021.USD","LU0320765646.SGD","LU0965509010.AUD","BK4127","LU2095319765.USD","SG9999001176.USD","LU0006306889.USD","LU2361045086.USD","LU1093756325.SGD","QBY","LU0082616367.USD","ROST","LU1989771016.USD","LU0432979614.USD","LU1989763005.USD","LU1804176565.USD","LU1718418525.SGD","RGYY","LU1929549753.HKD","SG9999002224.SGD","LU0640476718.USD","LU0965509101.SGD","LU2290526834.HKD","RGTI","LU1923622614.USD","LU0965508806.USD","LU1235294995.USD","WDAY","LU1941712348.USD","LU2360032135.SGD","LU1935042991.SGD","BK4581","IE0009355771.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4608","LU2506951875.HKD","LU2357627491.SGD","IE00B2B36J28.USD","LU1934455277.USD","LU1066051811.HKD","LU1162221912.USD","BK4588","LU0868494708.USD","LU1917777945.USD","IE00BBT3K403.USD","LU2468319806.SGD","LU2089984988.USD","BK4525","BK4528","LU0289739699.SGD","SG9999001440.SGD","LU1061106388.HKD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}